A Double-Blind, Randomized, Active-Controlled, Parallel-group, Phase 1/3 Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Latest Information Update: 26 Sep 2025
At a glance
- Drugs Daratumumab (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Celltrion
Most Recent Events
- 17 Jul 2025 Planned initiation date changed from 31 May 2025 to 20 Jul 2025.
- 17 Jul 2025 Status changed from not yet recruiting to recruiting.
- 09 May 2025 New trial record